Efficacy of targeted FasL in nasopharyngeal carcinoma
Open Access
- 1 December 2003
- journal article
- research article
- Published by Elsevier in Molecular Therapy
- Vol. 8 (6) , 964-973
- https://doi.org/10.1016/j.ymthe.2003.08.018
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Cisplatin chemotherapy plus adenoviral p53 gene therapy in EBV-positive and -negative nasopharyngeal carcinomaCancer Gene Therapy, 2001
- Lysosomal Protease Pathways to ApoptosisJournal of Biological Chemistry, 2001
- Adenoviralp53gene therapy promotes heat-induced apoptosis in a nasopharyngeal carcinoma cell lineInternational Journal of Hyperthermia, 2001
- Restricted Expression of an Adenoviral Vector Encoding Fas Ligand (CD95L) Enhances Safety for Cancer Gene TherapyMolecular Therapy, 2000
- Death Receptors: Signaling and ModulationScience, 1998
- Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage.The Journal of Experimental Medicine, 1995
- Adenoviruses as expression vectors and recombinant vaccinesTrends in Biotechnology, 1990
- Establishment and characterization of three transplantable EBV‐containing nasopharyngeal carcinomasInternational Journal of Cancer, 1988
- Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitorsAdvances in Enzyme Regulation, 1984
- Cytogenetic studies on an epithelial cell line derived from poorly differentiated nasopharyngeal carcinomaInternational Journal of Cancer, 1983